Intensity Therapeutics’ CEO, Lewis H. Bender, Named One of PharmaVOICE’s 100 Most Inspiring People for 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of the company’s proprietary therapeutic agents, today announced that the July/August issue of the publication PharmaVOICE has named Lewis H. Bender, the Company’s Founder, President and CEO, as one of its 100 most inspiring people for 2019. The issue features 100 of the top executives in the life sciences industry, including 17 entrepreneurs, the category for which Mr. Bender was chosen. The issue defines these individuals as visionary leaders who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.

“I am very humbled to be named to the PharmaVOICE 100 most inspiring people,” said Lewis H. Bender, Founder, President and CEO of Intensity Therapeutics, Inc. “Every day, 1700 people lose their fight against cancer. Our staff, directors and I are grateful to have been given the opportunity to try to make a difference in the lives of these brave men, women, children and their families. Our industry needs to do more to seek out and fund new ideas to battle disease.  Innovative solutions are not always found in the most well-known places.”

About Intensity Therapeutics

 Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRxSM technology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors.  INT230-6, Intensity’s lead product candidate, is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors. For more information, please visit and follow us on Twitter @IntensityInc.

Forward Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.